Leu16 scFv: a classic small-molecule antibody fragment targeting CD20

Author: Senior Product Manager of UA Views：8

This article focuses on the molecular characteristics and biological functions of the Leu16 single-chain variable fragment, systematically elaborating on its structural composition, antigen recognition properties, and molecular advantages as a derived fragment of a mouse anti-human CD20 monoclonal antibody, analyzing the targeting value conferred upon Leu16 scFv by CD20 as a stable surface marker of B-cell malignancies, and exploring its application strategies in B-cell-related immunotherapy research, genetic engineering modification, and immunological detection.

Recent Advances
Product Information

Recent Advances

Leu16 scFv: A Classic Small-Molecule Antibody Fragment Targeting CD20

Brief Introduction: This article focuses on the molecular characteristics and biological functions of the Leu16 single-chain variable fragment, systematically elaborating on the structural composition, antigen recognition properties, and molecular advantages of this derivative fragment of a mouse anti-human CD20 monoclonal antibody. It analyzes the targeting value conferred on Leu16 scFv by CD20 as a stable surface marker of B-cell malignancies, and explores its application strategies in B-cell-related immunotherapy research, genetic engineering modification, and immunological detection.

I. Molecular Origin and Structural Composition of Leu16 scFv

Leu16 scFv is a single-chain variable fragment derived from the mouse anti-human CD20 monoclonal antibody Leu16. Its molecular construction follows the classic design logic of single-chain antibodies: a flexible peptide linker connects the variable heavy chain and variable light chain, allowing the two variable regions to fold and pair on the same polypeptide chain while maintaining the specific antigen-binding activity of the parent antibody. The flexible peptide linker is typically composed of glycine and serine residues, providing the necessary spatial freedom for the two variable regions to ensure that a complete antigen-binding site can still form after folding. This structural design preserves the antigen recognition specificity of the parent antibody while compressing the molecule to the minimal functional antibody unit, providing a structural foundation for subsequent genetic engineering modification and multifunctional molecular assembly. As a classic CD20-targeting small-molecule antibody fragment, the molecular design of Leu16 scFv embodies the typical pathway of evolution from intact antibodies to engineered fragments.

II. Molecular Advantages and Functional Characteristics of Leu16 scFv

Leu16 scFv features low molecular weight, strong tissue penetration, low immunogenicity, and no Fc fragment interference compared with full-length monoclonal antibodies. These four characteristics together constitute its functional advantages over intact antibodies. Low molecular weight means better tissue permeability, enabling it to enter dense tissue regions that intact antibodies cannot effectively reach; strong tissue penetration directly improves its distribution uniformity in solid tissues. Low immunogenicity reduces the risk of anti-drug antibody production during repeated administration, making continuous application possible. The absence of the Fc fragment eliminates interference from Fc receptor-mediated nonspecific binding and Fc effector functions, allowing researchers to observe more purely the biological effects mediated by antigen recognition itself. The combination of these four advantages gives Leu16 scFv irreplaceable value in research scenarios that require precise dissection of antigen-binding functions or flexible assembly with effector molecules, where intact antibodies fall short.

III. Biological Basis of CD20 as a Target and the Targeting Value of Leu16 scFv

CD20 is a surface biomarker that is highly expressed and stable on mature B lymphocytes and most B-cell malignancies. It is expressed from the pre-B cell stage during B-cell development and persists through mature B cells, but is not expressed on plasma cells or hematopoietic stem cells; this expression profile makes it an ideal target for the treatment of B-cell-related diseases. Another important feature of CD20 is that it does not readily shed from the cell surface and does not cause significant receptor downregulation after antibody binding, providing conditions for sustained binding and action of antibody-based drugs. It is precisely on this biological basis of CD20 that Leu16 scFv has become a core targeting module in B-cell-related immunotherapy research. Its excellent specificity and binding affinity for the CD20 epitope have led to its preferential selection in various therapeutic molecular constructs as a molecular bridge connecting antigen recognition with effector functions.

IV. Applications of Leu16 scFv in Genetic Engineering and Immunological Research

Leu16 scFv has been extensively optimized and applied in genetic engineering and immunological research. In the field of genetic engineering, its coding sequence can serve as the core antigen recognition element for constructing chimeric antigen receptors, bispecific antibodies, and immunotoxins, achieving a complete functional chain from targeted recognition to effector execution through fusion with other functional modules. In the field of immunological research, Leu16 scFv can be used for detecting CD20 expression levels on the B-cell surface, analyzing B-cell subsets, and characterizing antibody-CD20 binding properties. In addition, because scFv can be readily recombinantly expressed in expression systems such as Escherichia coli, its preparation cost is relatively manageable, facilitating high-throughput screening and large-scale applications. These application scenarios together constitute the complete chain of Leu16 scFv extending from a basic research tool to a translational medicine component.

V. Conclusion

As a single-chain variable fragment derived from the mouse anti-human CD20 monoclonal antibody, Leu16 scFv has become a core targeting module in B-cell-related immunotherapy research by virtue of the parent antibody specificity maintained through the assembly of heavy and light chain variable regions via a flexible peptide linker, its molecular advantages of low molecular weight, strong tissue penetration, low immunogenicity, and no Fc interference, and the targeting value conferred by CD20 as a stable surface marker of B-cell malignancies. From CAR and bispecific antibody construction in genetic engineering to B-cell detection and binding characterization in immunological research, Leu16 scFv continues to drive the in-depth application of engineered antibody fragments in the field of B-cell-related diseases. The Leu16 scFv His Tag Protein provided by Youai offers reliable tool support for mechanistic research and targeted strategy development of Leu16 scFv, and will continue to facilitate innovative exploration in the field of B-cell immunotherapy.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next